Lung cancer is now the leading cause of cancer deaths in the United States, claiming more lives than several other major ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study, published in the International Journal of Molecular Science ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...

Shira Boehler shares her journey being diagnosed with Stage 1 lung cancer. A doctor explains the need for better lung cancer screening for asymptomatic, never smokers.

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Individuals with chronic obstructive pulmonary disease (COPD) are already compromised, so the prospect of removing all or part of a lung is especially daunting for these patients if they are also ...

(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...

In this study, researchers reported on 10-year follow-up of a phase 3 trial comparing surgery to chemoradiation boost in resectable, advanced NSCLC.